AKT1 and cardiomyopathy: More recently, hrAnxA1 was showed to protect against myocardial inflammation in type I diabetes–induced cardiomyopathy, a result obtained through dampening cardiac MAPK signaling and activating the prosurvival Akt pathway (24).